Intentional radioiodine ablation in Graves' disease.
In a series of 50 cases of Graves' disease qualifying for therapy with radioiodine, "ablative" doses of radioiodine resulted in hypothyroidism in 92% of cases at six months. Hypothyroidism was treated by thyroxine or tri-iodothyronine replacement therapy. Rapid responses and predictable outcome were regarded as important advantages. Intentional ablation is particularly convenient in situations where clinical and biochemical follow-up may be difficult. Further follow-up studies are needed to determine whether ablative therapy is the treatment of choice in all cases of Graves' disease.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006111:Graves Disease / Q000532:radiotherapy*; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy / Q000209:etiology; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D013960:Thyroid Function Tests; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013974:Thyroxine